Abstract
Andropause or male menopause is defined as androgen decline and onset of hypogonadism in the aging male. Testosterone deficiency in adult male is associated with diabetes mellitus, coronary artery disease, and heart failure. Type 2 diabetic male patients aged above 30 years showed low testosterone levels which is common in diabetic men and had symptoms of hypogonadism. Male sexual dysfunction among diabetic patients can include disorders of libido, ejaculatory problems, and erectile dysfunctions are common among people with diabetes, particularly in older men who had diabetes for years. Older diabetics tend to have both impaired insulin release as well as insulin resistance. There is growing evidence indicating the pathophysiological connections among the mechanisms of oxidative damage by disruption of the oxidative balance, increased levels of enzymatic glycation products in testicular region and glucose transporters, obesity and proinflammatory cytokines in male infertile patients with diabetes. Epidemiological studies suggest that many clinical findings in diabetics are linked to low testosterone levels. This article reviews pathophysiological mechanisms, observational studies, and clinical implications of testosterone therapy in type 2 diabetes mellitus.
Keywords: Testosterone, andropause, hypogonadism, insulin, diabetes mellitus, proinflammatory cytokines.
Current Pharmaceutical Design
Title:Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Volume: 23 Issue: 30
Author(s): Swathi Putta, Ilaria Peluso, Nagendra Sastry Yarla, Eswar Kumar Kilari, Anupam Bishayee, Da-Yong Lu, George E. Barreto, Ghulam Md Ashraf, Luciana Scotti, Marcus T. Scotti, Rajeev K. Singla, Thonos Alexiou, Atanas G. Atanasov, Vadim V. Tarasov, P. Veera Bramhachari, Sarat Babu Imandi, Madhuri Chintala, Bechan Sharma, Marcella Reale, Rosanna Filosa, Gjumrakch Aliev and Mohammad Amjad Kamal*
Affiliation:
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589,Saudi Arabia
Keywords: Testosterone, andropause, hypogonadism, insulin, diabetes mellitus, proinflammatory cytokines.
Abstract: Andropause or male menopause is defined as androgen decline and onset of hypogonadism in the aging male. Testosterone deficiency in adult male is associated with diabetes mellitus, coronary artery disease, and heart failure. Type 2 diabetic male patients aged above 30 years showed low testosterone levels which is common in diabetic men and had symptoms of hypogonadism. Male sexual dysfunction among diabetic patients can include disorders of libido, ejaculatory problems, and erectile dysfunctions are common among people with diabetes, particularly in older men who had diabetes for years. Older diabetics tend to have both impaired insulin release as well as insulin resistance. There is growing evidence indicating the pathophysiological connections among the mechanisms of oxidative damage by disruption of the oxidative balance, increased levels of enzymatic glycation products in testicular region and glucose transporters, obesity and proinflammatory cytokines in male infertile patients with diabetes. Epidemiological studies suggest that many clinical findings in diabetics are linked to low testosterone levels. This article reviews pathophysiological mechanisms, observational studies, and clinical implications of testosterone therapy in type 2 diabetes mellitus.
Export Options
About this article
Cite this article as:
Putta Swathi, Peluso Ilaria , Yarla Sastry Nagendra, Kilari Kumar Eswar , Bishayee Anupam, Lu Da-Yong, Barreto E. George , Ashraf Md Ghulam, Scotti Luciana, Scotti T. Marcus, Singla K. Rajeev, Alexiou Thonos, Atanasov G. Atanas, Tarasov V. Vadim, Bramhachari Veera P., Imandi Babu Sarat, Chintala Madhuri , Sharma Bechan , Reale Marcella , Filosa Rosanna, Aliev Gjumrakch and Kamal Amjad Mohammad *, Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications, Current Pharmaceutical Design 2017; 23 (30) . https://dx.doi.org/10.2174/1381612823666170823103830
DOI https://dx.doi.org/10.2174/1381612823666170823103830 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Prevention of Neointimal Hyperplasia by Local Application of Lentiviral Vectors Encoding Pin1 shRNA in Pluronic F127
Current Gene Therapy Epigenetic Regulation of Myocardial Homeostasis, Self-Regeneration and Senescence
Current Drug Targets Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Pharmacological Treatment of Vagal Hyperactivity, a Rare but Potentially Fatal Cause of Sudden Cardiac Death
Mini-Reviews in Medicinal Chemistry OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design